High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience
To access this article, please choose from the options below
PII: S0145-2126(04)00381-9
doi:10.1016/j.leukres.2004.10.009
© 2004 Elsevier Ltd. All rights reserved.
